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Background: The use of stereotactic body radiotherapy (SBRT) is rapidly increasing. Presently, the most accurate
method uses fiducial markers implanted near the tumor. A shortcoming of this method is that the beams turn off
during the majority of the respiratory cycle, resulting in a prolonged treatment time. Recent advances in collimation
technology have enabled continuous irradiation to a moving tumor. However, the lung is a dynamic organ
characterized by inhalation exhalation cycles, during which marker/tumor geometry may change (i.e., misalignment),
resulting in under-dosing to the tumor.
Findings: Eight patients with lung cancer who were candidates for stereotactic radiotherapy were examined with 4D
high-resolution CT. As a marker surrogate, virtual bronchoscopy using the pulmonary artery (VBPA) was conducted. To
detect possible marker/tumor misalignment during the respiration cycle, the distance between the peripheral
bronchus, where a marker could be implanted, and the center of gravity of a tumor were calculated for each
respiratory phase. When the respiration cycle was divided into 10 phases, the median value was significantly
larger for the 30%-70% respiratory phases compared to that for the 10% respiratory phase (P<0.05, Mann–Whitney
U-test).
Conclusions: These results demonstrate that physiological aspect must be considered when continuous tumor
tracking is applied to a moving tumor. To minimize an “additional” internal target volume (ITV) margin, a marker
should be placed approximately 2.5 cm from the tumor.
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Introduction
Recent technological developments in radiation therapy,
including body frames [1], infra-red light monitoring of
chest wall movement to predict tumor location [2], and
implanting fiducial markers (hereafter referred to simply
as “markers”) for direct tumor targeting [3], have
enabled high-dose radiation delivery to moving tumors,
such as non-small cell lung carcinoma (NSCLC). With
image guidance, most stage T1-2 NSCLC cases have be-
come curable, with a local control rate of approximately
80% [4]. In our real-time tumor tracking radiotherapy
system (RTRT), a beam becomes activated when* Correspondence: trout@hs.hokudai.ac.jp
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reproduction in any medium, provided the ormarkers fall into an end-exhale at 8 mm3 [5]. End-
exhale is suitable because it accounts for a relatively long
time spent in a respiration cycle [5]. However, other
phases are wasted, leading to prolonged treatment time
(i.e., 30–40 min in our facility), and possible associated
patient discomfort. Small but non-negligible skin doses
are another concern [6]. Tumor tracking radiotherapy
with a dynamic multi-leaf collimator (DMLC-RTRT)
may help address these problems; experiments are on-
going, focusing primarily on a collimation system latency
to follow tumor movement [7-9]. However, little re-
search has been conducted on possible problems arising
from marker/tumor geometry changes during respiration
cycles. In this study, we discuss the possible concerns of
DMLC-RTRT; the study concept is shown in Figure 1.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The marker/tumor geometry change concept. A possible fiducial/tumor misalignment at end-inhale (lower square). The pink circle is
the expected correct tumor position. If misalignment occurs, the radiation dose to the tumor (painted in red) will be lower than planned.
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Patients and imaging techniques
The present study included 8 patients with lung cancer
who were candidates for stereotactic radiotherapy.
Images were taken with a 64-Multi Detector-row Com-
puted Tomography (MDCT) instrument (TOSHIBA,
AquilionTSX-101A). The slice thickness was 2.0 mm
and a respiration synchronization device (Anzai Medical
AZ-733 V) was used. The scan was initiated after careful
observation, ensuring that respiratory waves were stable
on a monitoring screen [10]. Details about the 4D CT
reconstruction procedure are described in our previous
report [11]. Briefly, a respiratory-specific image was
created from 0% (end-exhale) to 100% with 10% incre-
ments. This study strictly followed the guidelines of the
Declaration of Helsinki and its amendments of 1983,
1989, 1996, as well as those of the internal ethics com-
mittee of our hospital. Median patient age was 78 years
(range: 48–87 years); the male/female ratio was 5:3. Six
patients had adenocarcinoma, one had squamous carci-
noma, and one had metastatic carcinoma. All patients
were node-negative; 4 patients had stage T1 tumors, 3
patients had stage T2 tumors, and 1 patient was not
staged because the tumor was metastatic.Figure 2 The distal bronchus and the center of gravity of the tumor. No
(yellow arrow). The center of gravity (blue arrow) was estimated by delineaImage interpretation
To detect possible marker/tumor misalignment during
the respiration cycle, the distance between the peripheral
bronchus, where a marker could be implanted, and the
center of gravity of a tumor were calculated for each re-
spiratory phase. Anatomical detection was performed on
a Digital Imaging and Communications in Medicine
(DICOM) viewer with the free software ImageJ [12]
(pixel size, 0.64 mm2). To improve anatomical detection,
images were enlarged two times.
The center of gravity of a tumor
Two board-certified radiologists contoured the tumor at
each respiratory phase image. The center of gravity of
the tumor was calculated from those images, and this
point was used as a reference for the marker/tumor dis-
tance (Figure 2).
Peripheral bronchi as surrogates for markers
The peripheral bronchi were used as surrogates for mar-
kers. The advantage of using bronchi is that they can be
selected at any distance from the center of gravity of a
tumor. The peripheral bronchi mentioned here have a
diameter ≤ 1.5 mm. Such distal bronchi were often notte that the distal bronchus is not visible, but can be detected by VBPA
ting the tumor contours (blue) at each respiratory phase on ImageJ.
Figure 3 The marker/tumor misalignments as a function of respiratory phase for the 25 distances. A statistically significant difference in
misalignment was observed between the 30%-70% respiratory phases and the 10% respiratory phase (P<0.05, Mann–Whitney U-test). The
horizontal line represents the median value for each respiratory phase.
Figure 4 Maximum misalignments. Maximum misalignments are
shown with respect to initial (i.e., at end-exhale) marker/tumor
geometry. Note that the misalignment of ≥2.5 mm did not occur in
cases with an initial marker/tumor distance of ≤2.5 cm.
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using the pulmonary artery (VBPA) [13]. This technique
was originally developed in our facility to better detect
peripheral bronchi (with a diameter ≤ 1.5 mm) to im-
prove biopsy success rates. We have found this to be a
very good tool for identification of the small bronchi
required in this study. The bifurcations of the peripheral
arteries were chosen as surrogate points for bronchi,
based on the principle that the bronchi always run to-
gether with the pulmonary arteries.
On average, the inter-observer difference both for the
center of gravity and bronchus-surrogate point was
0.4 mm (maximum, 0.8 mm). Contouring and distal-
bronchus detection using VBPA were performed inde-
pendently by the two board-certified radiologists. The
averages of the coordinates of the center of gravity and
the distal bronchus were used for misalignment
evaluation.
Results
An example of marker/tumor detection is shown in
Figure 2. A total of 25 distances (i.e., an average of
3 bronchi per patient) were calculated. The median mis-
alignment at each phase among the 25 distances is
shown in Figure 3. A statistically significant differences
in misalignment was observed between the 30%-70% re-
spiratory phases and the 10% respiratory phase (P<0.05,
Mann–Whitney U-test). When the initial marker/tumor
distances were divided into two categories―a) < 3 cm(n=7) and b) ≥ 3 cm (n=18)―the misalignment was lar-
ger for the latter group at the 40%-70% respiratory
phases (P<0.05, Mann–Whitney U-test). The maximum
misalignment with respect to the initial marker/tumor
geometry for each patient is plotted in Figure 4. Al-
though no statistically significant difference between
tumor/marker distance and misalignment was observed,
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be >2.5 mm in cases with a marker/tumor distance
of 2.5 cm.
Discussion
Misalignment may be greater for tumors located at the
base of the lung, where motion is greater. In fact, a
German research group demonstrated a large lung archi-
tecture movement above the diaphragm [14]; however, no
tumors were located above the diaphragm in the present
study. Special attention would be required for proper mar-
ker implantation of such tumors. These results imply that
it might be safer to increase the internal target volume
(ITV) margin in DMLC-RTRT compared to that of “near-
static” RTRT.
Considering the steep dose–response curve for stereo-
tactic radiotherapy of the lung, careful treatment plan-
ning is required when DMLC-RTRT is administered to a
case in which misalignment is >2.5 cm. Even a slight
misalignment could increase the chance of marginal re-
currence. For example, reducing the dose from 48 Gy/4
fr to 40 Gy/4 fr resulted in lower tumor control [5]. Cur-
rently, several markers are often inserted for tumor
tracking, potentially increasing treatment accuracy [15].
A group from the University of Texas Health Science
Center performed a phantom DMLC-RTRT study, in
which the displacement between the DMLC beam iso-
center and the marker therein ranged from 0.5-1.5 mm.
These researchers also reported that DMLC-RTRT
reduces the mean surrounding tissue dose by 43% when
compared to three-dimensional conformal radiation
therapy (3DCRT). The percentage of lung volume re-
ceiving at least 20 Gy (V20) therein will be reduced from
28% to 18%, and the dose to 20% of the lung volume
(D20) from 35.2 Gy to 15.0 Gy [16]. Another phantom
study evaluating a MLC for 4D radiotherapy in the lung
demonstrated that an MLC latency period of 570 ms
and DMLC-RTRT will be of clinical use, provided that
the respiration-related isocenter misalignment is within
2 mm [17]. This group also performed a series of experi-
ments using a prototype of kilovoltage/megavoltage
DMLC-RTRT and reported that the root-mean-square
errors in the beam-target alignment ranged from 3.1-
7.6 mm without tracking and were reduced to <1.5 mm
with tracking, except during the model-building period
(6 s) [18].
All of the studies mentioned above were phantom-
based; however, physiological factors must also be con-
sidered during clinical use. Targeting a moving lung
tumor is a state-of-the-art technology. Such advanced
engineering is most likely not available in most regional
hospitals. A practical solution is to use the “mid-
ventilation” method, in which an image from a set of 4D
scans represents the tumor in its time-averaged positionover the respiratory cycle (the mid-ventilation CT scan)
[19]. There is a consensus that an inter-fractional isocen-
ter shift is within 6 mm [20]. Cone-beam CT may be a
practical tool to determine the isocenter. So far, physical
characteristics have been intensively investigated for pre-
cise high-dose radiotherapy. However, biological aspects
may also need to be considered for this type of radio-
therapy. We have conducted irradiation experiments in
cancer cells that mimicked high-dose/fraction radiother-
apy. Cells that survived a 10-Gy radiation dose exhibited
higher motility and invasiveness in a three-dimensional
collagen gel [21]. Thus, such cells may implement
mechanisms to try to escape from the high-dose irra-
diation field. A new concept of a “biologically targeted
volume” may therefore be needed for precise high-dose
radiotherapy.
Conclusion
DMLC-RTRT is a rapidly developing-technique with
promising data from leading institutions. However, when
applying these techniques in a clinical setting, physio-
logical aspects must be considered, as shown in the
present study. It might be safer to place a marker ap-
proximately 2.5 cm from the tumor, to minimize an
“additional” ITV margin. Minimizing the ITV margin
may be beneficial for patients with multiple small lesions
or proximally located tumors that are associated with a
high risk of complications [22]. The value of 2.5 cm is a
rough estimate, and further study with more patients is
warranted to confirm the present findings.
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